As Anthropic made its Wall Street debut on Thursday in the largest IPO in history, CEO Dario Amodei reaffirmed the company’s commitment to developing AI responsibly. In his speech ahead of the Nasdaq opening bell, Amodei vowed that the AI company would not bend to either business or political pressure and would “remain under human control.”
Reading the speech from a printout, the CEO began by talking about Anthropic’s origins as a way to build powerful technology to help humanity — something that he said was inspired by the loss of his father to a disease that became curable just a few years later.
He acknowledged that while human intelligence had made diseases like the plague, smallpox, and polio history for most of the world, there were still too few scientists with too little time to make progress in other areas of disease. AI, he said, could help with this by working in concert with humans to further medical progress.
It’s telling that Amodei began with a story highlighting AI’s potentially life-saving applications, since he’s warned repeatedly about the risks of advancing the technology too quickly. In September, Amodei drew headlines when he outlined a plan to pace AI development, which included things like coordinating with other leading companies on safety standards and embedding evaluators from third-party organizations to verify that companies were following their safety commitments.
OpenAI CEO Sam Altman, Google DeepMind chief Demis Hassabis, and xAI owner Elon Musk said they agreed with Amodei’s position, although few concrete commitments have been made.
In this morning’s speech, Amodei again stressed the need to progress AI technology and the safety required in doing so. He referred to the “very real risks” of AI in the hands of bad actors, whether those were individuals or nation-states, and the potential for things like “economic disruption” and “losing control of AI systems.”
Anthropic believes these risks are avoidable, he noted, as long as there are safeguards in place. Amodei said the company would continue to be invested in the work of AI alignment and testing, and developing new ways to understand AI behavior so it could remain under human control.
“There is much work still to be done, and the most difficult safety work lies ahead of us,” he said. “The incredible talent of the company that has enabled us to build the most capable AI systems will need to be directed more so than it has already towards double and triple checking that those AI systems are safe and remain under human control.”
“And to state it unequivocally, we will pace the training and deployment of AI systems, taking as long as is necessary to have confidence that they are safe and will remain under human control,” Amodei concluded.
His sister, Anthropic co-founder Daniela Amodei, echoed these sentiments in an interview with CNBC on Thursday, noting that while the risks were real, the promise of AI was also “incredible.”
“We were really founded on this idea that it is our job to mitigate those risks, and I think we have to date done an incredible job doing that. We obviously have more work ahead of us, but we are deeply committed to safety,” she added.
The full text of Dario Amodei’s opening speech is below:
Thank you, Daniela. My co-founders and I started Anthropic because we believe that the most powerful technology of our time should be built for the benefit of humankind. Daniela and I lost our father to a disease that just a few years later became curable. I started my career in biology, hoping to help future cures come sooner. In the lab, I saw the vast thicket of complexity that scientists face when they’re trying to understand disease and develop new treatments. So many of the scientific tools that can cut through that thicket — tools for gene editing, tools for gene synthesis, tools for controlling brain cells with light — started as pure ideas. In other words, they came from thinking, from intelligence.
Human intelligence has already made diseases like plague, smallpox, and polio history for most of the world. But progress in other diseases has been too slow for so many patients and their families. Going from a great idea to a treatment can take decades. It took many years from the first discovery of a strange repeating pattern in DNA to the approval of the first treatment for a disease using CRISPR. Nature is full of these patterns, but we’ve had too little intelligence to decipher most of them. Too few scientists with too [little] time. Now we can build that intelligence. Whether it’s protein folding, drug design, cancer genetics, or clinical trial administration, scientists across many areas of biology and medicine are finding Claude can help them do their research in a fraction of the time it would have taken just a couple of years ago. I believe sufficiently powerful AI working in concert with humans, could compress a century of scientific and medical progress into a decade.
I don’t want to get ahead of myself. At this point, all we have are early results. Experiments and clinical trials will still take time, and although they involve slow and ponderous processes, I believe these processes can be substantially accelerated by AI, we hope that in the future fewer families miss a cure by a few years. Medicine is just a particularly vivid example, but there are many other applications of Claude. Our customers, the world’s most ambitious companies, nonprofits, and individual people, are already applying the intelligence we’ve built to stimulate economic growth, lift people out of poverty, protect democracy and free societies, even make everyday services like the DMV work better. We’re proud to work alongside them, and I’m extremely optimistic about what we can do together in the future.
At the same time, we’ve always been honest that this technology has very real risks. These range from misuse of the technology by individuals or by nation states to economic disruption to losing control of AI systems. We discuss these risks not because we think they are inevitable and we are building anyway, but because we think they are avoidable and we can avoid them. Avoiding them depends on the choices made by the people building AI. There is a gigantic difference between how AI will go if we pay little attention to safety versus how it will go if we are obsessed with safety. And an obsession with safety and public benefit has been built into Anthropic’s DNA from the start, from safeguards against biological and cyber risks to alignment training and testing to looking inside our models like an X-ray, Anthropic has pioneered methods for understanding and steering the behavior of AI and keeping it under human control. There is much work still to be done, and the most difficult safety work lies ahead of us, the incredible talent of the company that has enabled us to build the most capable AI systems will need to be directed more so than it has already towards double and triple checking that those AI systems are safe and remain under human control.
And to state it unequivocally, we will pace the training and deployment of AI systems, taking as long as is necessary to have confidence that they are safe and will remain under human control, we will not bend to either business nor political pressure. Today puts the company in a stronger financial position, and in doing so, only strengthens our resolve to do the right thing. If we can show it’s possible to make the right choices on safety and still build an incredibly successful company. Others in our industry will be inspired to do the same. We call this a race to the top.
When the race to the top is working properly, it doesn’t matter which company has the best models. Everyone wins because everyone is building safely. The race to the top works best when driven from the front of the pack, and we fully hope and expect to do so. But the goal is to make the whole industry better, regardless of whether Anthropic is winning or losing at any given time. The advent of machine intelligence is one of the seminal moments in human history, and we have a rare opportunity to shape it for the better. Thank you.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
